Overview: NGS Bradykinesia Panel Sequencing TestIntroduction: The NGS Bradykinesia Panel Sequencing Test sequences bradykinesia-related genes to diagnose movement disorders, causing slowness. Following 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected bradykinesia-related disorders, such as Parkinson's disease.
Other Names: Bradykinesia NGS Assay, Parkinson's Gene Panel.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Bradykinesia sequencing began in the 2000s with movement disorder research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences bradykinesia-related genes to diagnose movement disorders, guides treatment, and evaluates patients with slowness.
Test Parameters: 1. Bradykinesia Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of slowness, rigidity, or movement disorder symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document slowness, rigidity, tremor, or family history of movement disorders. Include current medications, especially levodopa.
Consent: Written consent required, detailing the tests purpose, movement disorder implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze bradykinesia-related genes (e.g., LRRK2, SNCA). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for movement disorder diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm bradykinesia-related disorders, guiding levodopa therapy or genetic counseling. Negative results may require clinical evaluation.
Specialist Consultation: Consult a neurologist for result interpretation and treatment planning.
Additional Supporting Tests: DaTscan, brain MRI, or neurological exam to confirm movement disorder diagnosis.
Test Limitations: Not all movement disorders are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Parkinson's Guidelines, 2023; Neurology, Postuma RB, 2022.
